Alvetex® named in the top ten life science innovations of 2010 by The Scientist magazine
06 December 2010
Sedgefield, UK. 1st December 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is proud to announce that Alvetex®, its breakthrough 3D cell culture technology, is among the winners of Th...
Reinnervate launches Alvetex®, a breakthrough product for enabling routine 3D cell culture
22 November 2010
Sedgefield, UK. 22nd November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, is very pleased to announce today the first commercial launch of Alvetex®, its breakthrough 3D cell cultur...
Reinnervate completes expansion into new purpose-built facility at NETPark
17 November 2010
Sedgefield, UK. 16th November 2010. Reinnervate, an innovative life sciences company driving the adoption of routine 3D cell culture, today announced its expansion into a new purpose-built research and production facility at NETPark near Se...
Reinnervate’s ec23® shown to enhance neuronal differentiation of human fetal neuroprogenitors and human embryonic stem cells
28 September 2010
The potency of Reinnervate’s ec23® to enhance neuronal differentiation when added to cell culture growth media has been demonstrated in a paper accepted for publication in the next issue of Journal of Neuroscience Methods.1 ec23®, which is ...
Reinnervate wins Chemistry Innovation / EPSRC Industrial CASE Award to fund development of Alvetex® for the 3D culture of liver cells
28 September 2010
Reinnervate has been granted a Chemistry Innovation Knowledge Transfer Network / EPSRC Industrial CASE Award to fund the development of a next-generation Alvetex® scaffold optimised for 3D hepatocyte culture. Enhanced 3D in vitro models of ...
Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP)
14 September 2010
Reinnervate has been accepted as a new member of the In Vitro Testing Industrial Platform (IVTIP). The Company joins a group of over 35 organisations from across Europe actively involved in developing technologies for in vitro testing with ...
Reinnervate secures £1.8 million of investment to support commercialisation of Alvetex
27 May 2010
Sedgefield, UK. 27th May 2010. Reinnervate, the life sciences company driving the adoption of routine 3D cell culture, today announced that it had successfully raised £1.8 million in new equity funding to complete the development of and sup...